Serological response to one intradermal or intramuscular hepatitis B virus vaccine booster dose in human immunodeficiency virus-infected nonresponders to standard vaccination

• Published in: Perspectives in clinical research 2014-07, Vol.5 (3), p.134-138
• Main Authors: Ramezani, Amitis, Janbakhsh, Alireza, Gol-Mohammadi, Maryam, Banifazl, Mohammad, Aghakhani, Arezoo, Eslamifar, Ali, Pournasiri, Zahra, Mahdavian, Behzad, Farazi, Ali-Asghar, Sofian, Masoomeh
• Format: Article
• Language: English
• Subjects: Analysis; Booster dose; Care and treatment; Dosage and administration; Health aspects; Hepatitis B vaccine; hepatitis B virus vaccination; HIV infection; human immunodeficiency virus; intradermal; intramuscular; nonresponder; Original; Serology
• ISSN: 2229-3485; 2229-5488
• DOI: 10.4103/2229-3485.134318

Hepatitis B virus (HBV) vaccination is recommended for all human immunodeficiency virus (HIV)-infected patients without HBV immunity. However, serological response to standard HBV vaccination is frequently suboptimal in this population and the appropriate strategy for revaccination of HIV-infected nonresponders remained controversial. We aimed to determine the serological response to one booster dose of HBV vaccine given by intradermal (ID) or intramuscular (IM) route in HIV-positive nonresponders to standard HBV vaccination. In this study, 42 HIV-infected nonresponders were enrolled. We randomized them to receive either 10 μg (0.5 mL) for ID (20 cases) or 20 μg (1 mL) for IM (22 cases) administration of HBV vaccine as a one booster dose. After 1 month, anti-HBs titer was checked in all cases. A protective antibody response (seroconversion) defined as an anti-HBs titer ≥10 IU/L. Seroconversion was observed in 47.6% of subjects after 1 ID dose. A total of 30% showed antibody titers above 100 IU/L. Except one case, all responders had CD4(+) >200 cells/mm(3). Mean anti-HBs titer was 146.5 ± 246 IU/L. After the one IM booster dose, seroconversion was observed in 50% of cases. A total of 36.3% of subjects had anti-HBs ≥100 IU/L. All responders had CD4(+) >200 cells/mm(3), except one case. Mean anti-HBs titer was 416.4 ± 765.6 IU/L. Responders showed significantly higher CD4(+) cell counts, in comparison to nonresponders (P < 0.001). One booster dose administered IM or ID to HIV-infected nonresponders resulted in similar rates of seroconversion, overall response rate 50%. However, higher anti-HBs titers observed more frequently in IM group.